UCB Bioproducts has been active in chemical peptide manufacturing for over 20 years. The division has approximately 300 employees located in Braine-l’Alleud just outside of Brussels, Belgium.
By merging the businesses, Lonza will be the only contract manufacturer with a historically successful track record of providing active pharmaceutical ingredients from any of the three peptide producing technologies.
These technologies are liquid phase peptide synthesis, solid phase peptide synthesis, and recombinant technology. The first two are chemical syntheses and the third is microbial fermentation.
The acquisition also provides Lonza with another global site to serve its customer base, in addition to the three sites, in Switzerland, the United States and Czech Republic.
“With this acquisition Lonza further strengthens its position as a worldwide leader in custom peptide manufacturing by continuing to develop the Braine l’Alleud site as a global centre of excellence for the development and manufacture of peptides,” commented Stefan Borgas, CEO of Lonza.